Sterling Capital Management LLC
Position in NBIX — Neurocrine Biosciences Inc
CIK 1329883
CHARLOTTE, NC
Position in NBIX
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$606,912
+$467,136 QoQ
Shares Held
3,601
+239.4% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#76
of 205 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 73%
Shared 0%
None 27%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Sterling Capital Management LLC holds $17,469,343 across 46 Drug Manufacturers - Specialty & Generic names. NBIX ranks #5 (3.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
282,750 | $9,579,569 | |
| 2 | VTRS |
Viatris Inc
|
227,731 | $3,616,368 | |
| 3 | HLN |
Haleon plc
|
86,415 | $806,251 | |
| 4 | UTHR |
UNITED THERAPEUTICS Corp
|
1,246 | $675,120 | |
| 5 | NBIX |
Neurocrine Biosciences Inc
This page
|
3,601 | $606,912 | |
| 6 | LNTH |
Lantheus Holdings, Inc.
|
4,527 | $502,225 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
14,866 | $365,852 | |
| 8 | ZTS |
Zoetis Inc.
|
5,017 | $360,521 |
All Filings in NBIX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $606,912 | 3,601 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $139,776 | 1,061 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $201,398 | 1,420 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $139,116 | 991 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $132,728 | 1,056 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $36,940 | 334 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $220,038 | 1,612 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $210,046 | 1,823 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||